Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714657 · ClinicalTrials.gov registry record · Phase 2
Shortened Course Adjuvant Radiotherapy Following TORS
A Phase 2 study of HPV-Associated Oropharyngeal Squamous Cell Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 3
- Study locations
NCT05714657: Active Phase 2 study of HPV-Associated Oropharyngeal Squamous Cell Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05714657 is a Phase 2 study of HPV-Associated Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 104 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714657, a Phase 2 study of HPV-Associated Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a single-arm, phase II study to establish the safety of reducing radiation dose in selected HPV-Associated OPSCC patients receiving adjuvant radiation after TORS and neck dissection. This protocol also allows for sparing of the primary resection bed, in appropriate patients, as previously published by our group and found to be safe and effective.
Primary Outcome
To determine whether disease recurs locally (at primary site) or in regionally in the nodes of the neck
Conditions Studied
Interventions
- RADIATION Shortened Course Adjuvant Radiotherapy Following TORS
Study Locations (3)
Pennsylvania
- Lancaster General Hospital - Lancaster
- University of Pennsylvania - Philadelphia
- Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What the registry record for NCT05714657 still lists
NCT05714657 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower).
The record links to 1 condition, with HPV-Associated Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Shortened Course Adjuvant Radiotherapy Following TORS is the first listed.
NCT05714657 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05714657 about?
NCT05714657 is a clinical study titled "Shortened Course Adjuvant Radiotherapy Following TORS". This is a single-arm, phase II study to establish the safety of reducing radiation dose in selected HPV-Associated OPSCC patients receiving adjuvant radiation after TORS and neck dissection. This protocol also allows for sparing of the primary resection bed, in appropriate patients, as previously pu...
What is the current status of trial NCT05714657?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2023-01-30. Estimated completion is 2026-04-30.
What conditions does trial NCT05714657 study?
This clinical trial studies the following conditions: HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05714657?
The interventions under investigation include: Shortened Course Adjuvant Radiotherapy Following TORS (RADIATION).
Who is sponsoring clinical trial NCT05714657?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714657 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05714657's enrollment target sits among peer trials
104 660th of 2000 higher than 1,337 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI